Sarepta Therapeutics (NASDAQ:SRPT): An FDA panel voiced safety concerns about Kynamro, which is a PS-ASO drug, and JMP Securities thinks that the concerns have the ability to affect Sarepta’s competitor in Duchene Muscular Dystrophy, GlaxoSmithKline’s (NYSE:GSK) PRO051. The firm also mentions that Sarepta’s drug is not a PS-ASO, and it keeps its Outperform rating on the stock.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP): Forbes published an article that calls into question the validity of the Phase II results for Ziopharm’s palifosfamide and its commercial viability, but JMP Securities has decided to continue to be confident concerning the validity of the Phase II results and remains upbeat regarding the probablility for positive Phase III results. The firm keeps its Outperform rating and a $10 target on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Domino’s Pizza, Inc. (NYSE:DPZ): Oppenheimer met with Domino’s Pizza’s management, and the firm now believes that the company’s comps are in the ideal position to accelerate as the company’s earnings should beat expectations. The firm reiterates its Outperform rating on the stock.
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Stifel Nicolaus surveyed 35 hematology/oncology specialists, and the firm now believes that the survey indicates that ARIAD’s ponatinib in front-line CML showed significant potential. The firm believes that the company’s outlook for the drug’s selling continues to be conservative, and it keeps its Buy rating on the stock.
Array BioPharma, Inc. (NASDAQ:ARRY): After it met with Array’s management, Stifel Nicolaus continues to be convinced that the company’s hematology/oncology assets will continue to grow over the longer term. The firm continues to be upbeat regarding the company’s outlook for the company’s ARRY-614, and it believes that investor sentiment towards its ARRY-520 will show improvement when more data is released.